BR100 Increased By (0.68%)
BR30 Increased By (0.95%)
KSE100 Increased By (0.53%)
KSE30 Increased By (0.57%)
BECO 6.15 Increased By ▲ 0.38 (6.59%)
BML 52.70 Decreased By ▼ -0.30 (-0.57%)
BOP 34.53 Increased By ▲ 0.54 (1.59%)
CNERGY 8.14 Increased By ▲ 0.03 (0.37%)
DCL 12.17 Decreased By ▼ -0.03 (-0.25%)
FCCL 53.42 Increased By ▲ 0.59 (1.12%)
FCSC 5.19 Increased By ▲ 0.12 (2.37%)
FFL 18.05 Increased By ▲ 0.10 (0.56%)
FNEL 1.32 Increased By ▲ 0.03 (2.33%)
HUMNL 10.88 No Change ▼ 0.00 (0%)
KEL 8.08 Increased By ▲ 0.06 (0.75%)
KOSM 5.39 Decreased By ▼ -0.13 (-2.36%)
MLCF 87.35 Increased By ▲ 0.84 (0.97%)
NBP 187.25 Increased By ▲ 2.09 (1.13%)
PACE 10.72 Increased By ▲ 0.14 (1.32%)
PAEL 39.87 Increased By ▲ 0.45 (1.14%)
PIAHCLA 26.17 Decreased By ▼ -0.05 (-0.19%)
PIBTL 17.04 Increased By ▲ 0.37 (2.22%)
PPL 230.00 Increased By ▲ 1.82 (0.8%)
PRL 34.84 Increased By ▲ 0.16 (0.46%)
PTC 67.15 Increased By ▲ 1.82 (2.79%)
SEARL 90.80 Increased By ▲ 0.67 (0.74%)
SSGC 26.82 Increased By ▲ 0.22 (0.83%)
TELE 8.63 Increased By ▲ 0.35 (4.23%)
THCCL 58.50 No Change ▼ 0.00 (0%)
TPLP 8.64 Increased By ▲ 0.42 (5.11%)
TREET 24.70 Increased By ▲ 0.17 (0.69%)
TRG 69.90 Increased By ▲ 0.19 (0.27%)
WAVES 10.09 Increased By ▲ 0.15 (1.51%)
WTL 1.29 Increased By ▲ 0.01 (0.78%)
By

LONDON: Britain will start rolling out Pfizer's COVID-19 pill to vulnerable people next month, the health ministry said on Friday, targeting the treatment at people with compromised immune systems for whom the vaccine can be less effective.

The health ministry said that Pfizer's antiviral treatment Paxlovid, a combination of Pfizer's pill with an older antiviral ritonavir, will be made available to thousands of people from Feb. 10.

"It is fantastic news that this new treatment, the latest cutting-edge drug that the NHS is rolling out through new COVID-19 medicine delivery units, will now be available to help those at highest risk of COVID-19," National Health Service medical director Stephen Powis said.

Britain approves Pfizer's antiviral COVID-19 pill

"Trials have shown it can reduce hospitalisation and risk of death by 88%, meaning we'll be in the best position to save thousands of lives."

Britain has ordered 2.75 million courses of Paxlovid, and the government said that it would set out further details on access to the treatment soon but that people who are immunocompromised, cancer patients or those with Down's Syndrome could be able to access it directly.

Merck's COVID-19 pill active against Omicron in lab studies

It is the second antiviral being rolled out in Britain after molnupiravir, a pill made by Merck and Ridgeback Biotherapeutics which is being deployed to patients through the Panoramic trial.

Comments

Comments are closed for this article.